Following a series of changes to the technologies due to be appraised, NICE considers there is limited value to the NHS in conducting an MTA of the remaining second line renal cell carcinoma therapies (axitinib, sorafenib and sunitinib). The Institute has decided to remove this appraisal from its current work programme.
|
Status
|
Suspended
|
| Process |
MTA
|
Project Team
| Project lead |
Stephanie Yates |
Email enquiries
Consultees
| Companies sponsors |
Bayer (sorafenib) |
| |
Novartis Pharmaceuticals (everolimus) |
| |
Pfizer (axitinib and sunitinib) |
| Others |
Department of Health |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Kidney Cancer Support Network |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Nursing |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
Commentators
| Associated public health groups |
None |
| Comparator companies |
None |
| General commentators |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| Relevant research groups |
National Cancer Research Institute |